Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of anagrelide retard in at-risk essential thrombocythaemia
2009-017095-24Phase 3Completed
- Sponsor
- AOP Health
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in thrombocythemia comparing Anagrelide retard with Placebo (2 arms). Primary endpoint: Time to first clinically significant ET-related event. Started Feb 2010; status: completed.
02
Drugs
anagrelide
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on 2009-017095-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017095-24.